Masimo (MASI) late Tuesday said Katie Szyman has been selected as the new chief executive officer at the medical device company, succeeding interim CEO Michelle Brennan, who was appointed to be the new chair of Masimo's board of directors.
Both moves take effect on Feb. 12, the company said.
Szyman currently is the worldwide president for advanced patient monitoring at Becton, Dickinson (BD) and previously led the critical care product group at Edwards Lifesciences before its acquisition by BD in September 2024.
Brennan temporarily became CEO at Masimo on Sept. 25 after Joe Kiani disclosed plans to step down from the company. The former Johnson & Johnson senior executive was elected to the Masimo board in 2023.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。